Search Bar & Filters
Found 34 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the treatment of anemia in patients with chronic kidney disease CKD who are on hemodialysis. This Phase III, investigator-blinded, randomized, multicenter study compares two drugs, efepoetin alfa and darbepoetin alfa, to see how well they maintain hemoglobin levels in these patients. The study aims to maintain hemoglobin between 10.0 gdL and 12.0 gdL, which is important for managing anemia in CKD. Participants will be randomly assigned in a 21 ratio to receive either efepoetin alfa or darbepoetin alfa. Both drugs are given by intravenous injection, typically after dialysis sessions. Efepoetin alfa is administered weekly from Day 1 to Week 28, with possible interval changes to one or two weeks from Week 29 to Week 52 based on investigator judgment. The study consists of three periods screening up to 28 days, treatment about 52 weeks, and a 4-week follow-up with phone contacts up to Week 56 or the last visit. During the study, participants will undergo regular assessments including hemoglobin level monitoring to evaluate the mean change between Week 20 and Week 28. Safety and efficacy are closely observed, with dosages adjusted to maintain target hemoglobin levels. Follow-up will include phone contacts to monitor participants up to Week 56. The total participation duration is approximately one year, starting from screening through treatment and follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of regimens containing quabodepistat for treating rifampicin-resistant or multidrug-resistant pulmonary tuberculosis in this Phase 3, randomized, open-label, multicenter trial. Participants are divided into two groups based on fluoroquinolone susceptibility and randomized to receive either experimental or control treatment regimens. The study aims to provide shorter, well-tolerated treatment options for drug-resistant tuberculosis. Participants with fluoroquinolone-susceptible tuberculosis are randomized to a 4-month experimental regimen including bedaquiline, pretomanid, quabodepistat, and moxifloxacin or a 6-month control regimen with bedaquiline, pretomanid, linezolid, and moxifloxacin. Those with fluoroquinolone-resistant tuberculosis receive either a 6-month experimental regimen of bedaquiline, pretomanid, and quabodepistat or a 6-month control regimen of bedaquiline, pretomanid, and linezolid. Doses vary by drug and regimen, with some adjustments permitted for toxicity. Participants are followed for approximately 16 months after randomization, with evaluations including sputum samples, chest X-rays, and monitoring of adverse events. The main outcome measured is the proportion of participants with unfavorable outcomes at 12 months post-randomization. Other assessments include treatment-emergent adverse events, sputum culture conversion, relapse, and reinfection. Follow-up visits may extend to week 72 for ongoing safety or relapse monitoring.
Actively Recruiting
Researchers are evaluating the efficacy and safety of a combination therapy using BR1019A and BR1019B in patients who have both essential hypertension and type 2 diabetes mellitus. This phase 3 clinical trial aims to understand how this combination affects blood pressure and blood sugar control in this patient group. Participants will receive daily doses of investigational products including BR1019A, BR1019B, and BR1019C or their variants, taken once a day for 12 weeks. The study has multiple groups comparing different combinations of these drugs to observe their effects over this treatment period. During the trial, participants will be monitored for changes in systolic blood pressure and HbA1c levels from baseline at 12 weeks. Safety and efficacy assessments will be conducted throughout the treatment period. The total study duration extends up to December 2026, with participants expected to adhere to the daily medication schedule and visit the study sites as required for evaluations.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
Actively Recruiting
Researchers are gathering real-world data on the outcomes of patients with perimembranous ventricular septal defects PmVSD, a heart condition, who have undergone transcatheter closure using various device occluders. This international, multicenter, non-interventional, observational study aims to evaluate how well these devices work and their safety when used in both children and adults. The study focuses on patients treated with devices either specifically designed for PmVSD closure or used off-label. Participants in this study have had their PmVSD closed using commercially available occluder devices through a transcatheter procedure. The devices are placed without open-heart surgery to close the defect. The study observes patients who have already undergone this procedure and collects follow-up data according to each hospitals usual practice. The study does not intervene but monitors how these devices perform over time. Participants will be followed for up to 60 months after their procedure to assess clinical success, technical success, closure success, and any device-related complications. Researchers will also evaluate functional outcomes and quality of life for up to 48 months post-procedure. Data collection includes clinical events from the implant attempt through the follow-up period, and safety is monitored by tracking adverse events. The total duration of participation depends on the timing of the procedure and follow-up visits according to local protocols.
Actively Recruiting
The trial investigates pain management after mastectomy for breast cancer, focusing on comparing two regional analgesia techniques. It aims to evaluate the pain relief and quality of recovery between a combined Pectoral Nerve II PECS II and Superficial Parasternal Intercostal Plane PIP block versus the standard Thoracic Paravertebral Block TPVB. This study addresses risks related to TPVB and explores whether the combined blocks can provide effective pain control with fewer complications. Participants are randomly assigned to one of two groups following general anesthesia induction one receiving the combined ultrasound-guided PECS II and PIP blocks with specific doses of 0.25% Bupivacaine, and the other receiving the ultrasound-guided TPVB at thoracic levels T4 and T6. Both groups receive standardized general anesthesia and intraoperative monitoring. Postoperative pain management includes oral paracetamol, IV ketorolac, and IV Morphine via patient-controlled analgesia PCA. During the 24-hour postoperative period, participants have their pain levels assessed at rest and movement using the Numeric Rating Scale NRS at multiple time points. Researchers also measure total opioid use, time to first analgesic request, and quality of recovery using the QoR-15 questionnaire. Monitoring for complications related to nerve blocks, such as local anesthetic toxicity and pneumothorax, is conducted, ensuring comprehensive safety and efficacy evaluation throughout the study.
Actively Recruiting
Researchers are studying the use of different antibiotic treatments for newborns with all-risk asymptomatic congenital syphilis, a condition passed from mother to baby during pregnancy. This phase II study aims to evaluate the safety and how the body processes these antibiotics in newborns, comparing three different treatment options. The treatments being evaluated include a 10-day course of oral Linezolid given twice daily, a 10-day course of oral Amoxicillin given twice daily, and a single intramuscular injection of Benzathine Penicillin G. Participants are randomly assigned to one of these three treatment groups to compare their effects. During the study, newborns will be closely monitored from enrollment through 10 days of treatment, with assessments including blood and cerebrospinal fluid antibiotic levels and tracking any adverse events up to 24 weeks. Researchers will also evaluate clinical outcomes over this period. The total participation may last up to 24 weeks to ensure safety and effectiveness monitoring.
Actively Recruiting
This research aims to gather more information on the safety, effectiveness, and performance of the DynamX Coronary Bioadaptor System in treating patients with ischemic heart disease caused by new native coronary artery lesions. It focuses on a real-world patient population with coronary artery disease to confirm how well this device works and its safety when used in routine medical care. All participants in the study will receive at least one implant of the DynamX Novolimus-eluting Coronary Bioadaptor System during a percutaneous coronary intervention PCI procedure. The device will be used following the products instructions in a commercial setting. This registry monitors the devices performance and outcomes over time without altering the usual care process. During the study, patients will be followed to assess clinical outcomes such as device success, procedural success, and various cardiovascular events including myocardial infarction, revascularization, stroke, and death. These outcomes will be tracked at hospital stay, 30 days, and 12 months after the procedure. The study also collects data on the duration of dual antiplatelet therapy DAPT and will monitor device safety and effectiveness throughout the follow-up period, which extends up to 12 months and beyond.
Actively Recruiting
Endometriosis is a long-lasting condition affecting 10-15% of women of childbearing age, commonly causing pelvic pain. Researchers are evaluating the effects of the drug triptorelin, a treatment approved in Indonesia for endometriosis symptoms, to compare dosing intervals and their impact on pain and hormone levels. This study aims to assess whether extending the dose interval can reduce side effects and improve patient adherence while effectively managing symptoms. Participants will be divided into two groups receiving triptorelin over an 18-week period. The first group will receive three doses two before surgery at baseline and week 6, and one after surgery at week 12. The second group will receive a single dose after surgery at week 12. The study is open label and non-randomized, with visits every six weeks to monitor treatment effects. During the study, participants will have their pain levels measured using a visual analogue scale VAS at baseline, week 6, week 12 before surgery, and week 18. Blood tests will assess Anti Mullerian Hormone AMH and estradiol levels at baseline and week 12. Additionally, surgical evaluation will assess the condition of the uterus and cysts. This approach allows researchers to observe hormone changes, pain improvement, and physical condition related to endometriosis treatment over time.
1-10 of 34
1